• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    NEXTracker Posts Upbeat Earnings, Joins monday.com, Nu Holdings And Other Big Stocks Moving Higher On Wednesday

    5/15/24 10:21:59 AM ET
    $ARQT
    $ARVN
    $BCRX
    $BGS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ARQT alert in real time by email

    U.S. stocks were higher, with the Dow Jones gaining around 150 points on Wednesday.

    Shares of Nextracker Inc. (NASDAQ:NXT) rose sharply during Wednesday's session after the company reported better-than-expected fourth-quarter financial results.

    NEXTracker posted quarterly earnings of 96 cents per share, beating market estimates of 78 cents per share. The company's quarterly sales came in at $736.51 million versus expectations of $683.43 million, according to data from Benzinga Pro.

    Nextracker shares gained 7.7% to $46.34 on Wednesday.

    Here are some other big stocks recording gains in today's session.

    • monday.com Ltd. (NASDAQ:MNDY) gained 21.5% to $220.93 after the company reported better-than-expected first-quarter financial results and issued FY24 revenue guidance above estimates.
    • BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) surged 20% to $6.44.
    • Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) gained 16.5% to $9.47 after the company reported better-than-expected first-quarter financial results.
    • Codere Online Luxembourg, S.A. (NASDAQ:CDRO) gained 14.3% to $7.98 following first-quarter results.
    • Riskified Ltd. (NYSE:RSKD) climbed 12.8% to $6.05 following upbeat results.
    • Cabaletta Bio, Inc. (NASDAQ:CABA) rose 12.8% to $12.66 following first-quarter results.
    • B&G Foods, Inc. (NYSE:BGS) gained 11.5% to $9.53.
    • J.Jill, Inc. (NYSE:JILL) rose 9.7% to $31.17. J.Jill said it sees first-quarter preliminary net sales results of about $160 million and adjusted EBITDA of $33 million to $34 million.
    • Candel Therapeutics, Inc. (NASDAQ:CADL) rose 9.3% to $11.69. Candel Therapeutics posted a first-quarter loss of 28 cents per share on Tuesday.
    • GoodRx Holdings, Inc. (NASDAQ:GDRX) climbed 8.1% to $7.18 after the company announced that it signed a new direct contracting agreement with Kroger.
    • Arvinas, Inc. (NASDAQ:ARVN) rose 7.3% to $33.64.
    • Nu Holdings Ltd. (NYSE:NU) gained 7.1% to $12.36 after the company reported better-than-expected first-quarter sales results. Also, Susquehanna maintained a Positive rating on the stock and raised its price target from $12 to $14.
    • Shift4 Payments, Inc. (NYSE:FOUR) rose 6.8% to $69.46.
    • Critical Metals Corp. (NASDAQ:CRML) gained 6.2% to $8.60.
    • Dell Technologies Inc. (NYSE:DELL) gained 6% to $142.18 after Morgan Stanley maintained an Overweight rating on the stock and raised its price target from $128 to $152.
    • Celestica Inc. (NYSE:CLS) rose 5.4% to $50.57.
    • Vodafone Group Public Limited Company (NASDAQ:VOD) gained 4.2% to $9.58.

    Now Read This: Top 3 Real Estate Stocks That May Implode In Q2

    Get the next $ARQT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ARQT
    $ARVN
    $BCRX
    $BGS

    CompanyDatePrice TargetRatingAnalyst
    monday.com Ltd.
    $MNDY
    2/23/2026$80.00Buy → Hold
    Jefferies
    BioCryst Pharmaceuticals Inc.
    $BCRX
    2/18/2026$17.00Outperform
    Evercore ISI
    monday.com Ltd.
    $MNDY
    2/10/2026$80.00Buy → Hold
    Loop Capital
    monday.com Ltd.
    $MNDY
    2/10/2026$90.00Outperform → Neutral
    Robert W. Baird
    Codere Online Luxembourg S.A.
    $CDRO
    1/30/2026$8.50Buy → Hold
    Stifel
    Celestica Inc.
    $CLS
    1/28/2026$400.00Buy
    BofA Securities
    Nextpower Inc.
    $NXT
    1/28/2026$142.00Sector Weight → Overweight
    KeyBanc Capital Markets
    Nextpower Inc.
    $NXT
    1/28/2026$88.00 → $105.00Hold
    TD Cowen
    More analyst ratings

    $ARQT
    $ARVN
    $BCRX
    $BGS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Chang David J. bought $19,888 worth of shares (8,800 units at $2.26) (SEC Form 4)

    4 - Cabaletta Bio, Inc. (0001759138) (Issuer)

    1/21/26 6:56:58 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President, Science & Tech. Binder Gwendolyn bought $24,763 worth of shares (11,312 units at $2.19), increasing direct ownership by 57% to 31,312 units (SEC Form 4)

    4 - Cabaletta Bio, Inc. (0001759138) (Issuer)

    1/21/26 6:56:30 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Tomasello Shawn bought $50,322 worth of shares (22,725 units at $2.21) (SEC Form 4)

    4 - Cabaletta Bio, Inc. (0001759138) (Issuer)

    1/21/26 6:55:49 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ARQT
    $ARVN
    $BCRX
    $BGS
    SEC Filings

    View All

    SEC Form 6-K filed by Nu Holdings Ltd.

    6-K - Nu Holdings Ltd. (0001691493) (Filer)

    2/25/26 4:24:36 PM ET
    $NU
    Finance: Consumer Services
    Finance

    SEC Form 6-K filed by Nu Holdings Ltd.

    6-K - Nu Holdings Ltd. (0001691493) (Filer)

    2/25/26 4:22:05 PM ET
    $NU
    Finance: Consumer Services
    Finance

    SEC Form 6-K filed by Nu Holdings Ltd.

    6-K - Nu Holdings Ltd. (0001691493) (Filer)

    2/25/26 4:19:26 PM ET
    $NU
    Finance: Consumer Services
    Finance

    $ARQT
    $ARVN
    $BCRX
    $BGS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ZORYVE issued to ARCUTIS BIOTHERAPEUTICS INC

    Submission status for ARCUTIS BIOTHERAPEUTICS INC's drug ZORYVE (ORIG-1) with active ingredient ROFLUMILAST has changed to 'Approval' on 12/15/2023. Application Category: NDA, Application Number: 217242, Application Classification: Type 3 - New Dosage Form

    12/19/23 3:40:08 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for ZORYVE issued to ARCUTIS BIOTHERAPEUTICS INC

    Submission status for ARCUTIS BIOTHERAPEUTICS INC's drug ZORYVE (ORIG-1) with active ingredient ROFLUMILAST has changed to 'Approval' on 12/15/2023. Application Category: NDA, Application Number: 217242, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination

    12/15/23 5:01:31 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARQT
    $ARVN
    $BCRX
    $BGS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Accounting Officer Loomis David K sold $13,473 worth of shares (1,108 units at $12.16), decreasing direct ownership by 4% to 29,692 units (SEC Form 4)

    4 - ARVINAS, INC. (0001655759) (Issuer)

    2/25/26 5:09:32 PM ET
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Scientific Officer Cacace Angela M sold $43,885 worth of shares (3,609 units at $12.16), decreasing direct ownership by 2% to 147,623 units (SEC Form 4)

    4 - ARVINAS, INC. (0001655759) (Issuer)

    2/25/26 5:09:10 PM ET
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Teel Randy sold $58,198 worth of shares (4,786 units at $12.16), decreasing direct ownership by 3% to 149,696 units (SEC Form 4)

    4 - ARVINAS, INC. (0001655759) (Issuer)

    2/25/26 5:08:46 PM ET
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARQT
    $ARVN
    $BCRX
    $BGS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nu Holdings Ltd. Reports Fourth Quarter and Full Year 2025 Financial Results

    Nu Holdings Ltd. (NYSE:NU) ("Nu" or the "Company"), one of the largest digital financial services platforms in the world, today released its financial results for the fourth quarter and full year ended December 31, 2025, prepared in accordance with IFRS, as well as complementary managerial1 results. The financial statements and earnings presentation are available on the Company's Investor Relations website at www.investors.nu, along with details of the earnings conference call to be held today at 5:00 p.m. Eastern Time / 7:00 p.m. Brasília time. "In Q4'25, we increased scale, deepened engagement, and expanded profitability, closing the year with 131 million customers and 17 million net ad

    2/25/26 4:50:00 PM ET
    $NU
    Finance: Consumer Services
    Finance

    Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    Q4 2025 net product revenue for ZORYVE® (roflumilast) was $127.5 million, an 84% increase compared to Q4 2024, and a 29% increase compared to Q3 2025Full year 2025 net product revenue for ZORYVE was $372.1 million, an increase of 123% over the prior yearReported positive topline data for the INTEGUMENT-INFANT Phase 2 trial of ZORYVE cream 0.05% in children ages 3 to 24 months with mild to moderate atopic dermatitis, with a Supplemental New Drug Application (sNDA) submission expected in Q2 2026Announced expansion of its dermatology sales force and, separately, the initiation of a targeted Arcutis commercialization effort for primary care and pediatric health care providersProduced positive op

    2/25/26 4:00:00 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dell PowerEdge XR9700 Brings Cloud RAN and AI to Harsh Edge Environments

    Liquid-cooled, weather-resistant server enables zero-footprint deployments in extreme outdoor conditions, expanding network capacity where space and power are constrained Industry's first outdoor x86 server for cloud RAN and edge applications1 Closed-loop liquid-cooled, ultra-compact, weather-resistant server will accelerate cloud RAN, edge computing and AI use cases in extreme environments including utility poles, rooftops and beyond New server will enable open compute capabilities at zero-footprint locations Dell Technologies (NYSE:DELL) introduces the Dell PowerEdge XR9700 server, a first of its kind closed-loop liquid-cooled, fully-enclosed, ruggedized server engineered to r

    2/25/26 9:00:00 AM ET
    $DELL
    Computer Manufacturing
    Technology

    $ARQT
    $ARVN
    $BCRX
    $BGS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Monday.com downgraded by Jefferies with a new price target

    Jefferies downgraded Monday.com from Buy to Hold and set a new price target of $80.00

    2/23/26 8:32:39 AM ET
    $MNDY
    Computer Software: Prepackaged Software
    Technology

    Evercore ISI resumed coverage on BioCryst Pharma with a new price target

    Evercore ISI resumed coverage of BioCryst Pharma with a rating of Outperform and set a new price target of $17.00

    2/18/26 8:21:17 AM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Monday.com downgraded by Loop Capital with a new price target

    Loop Capital downgraded Monday.com from Buy to Hold and set a new price target of $80.00

    2/10/26 8:00:13 AM ET
    $MNDY
    Computer Software: Prepackaged Software
    Technology

    $ARQT
    $ARVN
    $BCRX
    $BGS
    Leadership Updates

    Live Leadership Updates

    View All

    Treasury Guidance Supports T1's Tax Credit Eligibility

    AUSTIN, Texas and NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- T1 Energy Inc. (NYSE:TE) ("T1," "T1 Energy," or the "Company") supports policy that favors the revival of advanced American manufacturing and energy dominance in accordance with the One Big Beautiful Bill Act ("OBBBA"). The initial guidance provided by the U.S. Department of Treasury last week on the implementation of the OBBBA foreign entity of concern ("FEOC") provisions is consistent with T1's expectations and supports T1's analysis of its eligibility for Section 45X tax credits. "T1 is an American-owned and controlled company committed to investing in advanced American manufacturing, building a domestic and non-FEOC solar s

    2/17/26 6:10:23 AM ET
    $GLW
    $NXT
    $TE
    Telecommunications Equipment
    Industrials
    Industrial Machinery/Components
    Miscellaneous

    Critical Metals Corp. Appoints Key Project Delivery Team to Fast Track Tanbreez Development

    NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Critical Metals Corp. (NASDAQ:CRML) ("Critical Metals Corp" or the "Company"), a leading critical minerals mining company, is pleased to announce that it has appointed to the Group a highly experienced Project Management Team to fast-track the development of its flagship Tanbreez Project. The Company's CEO has appointed a world-class team of highly experienced and successful mining, processing, and logistics professionals who have delivered large-scale projects globally over several decades. In the current environment, with extremely high demand for talent for developing rare earth assets to counter China's stranglehold, the best in the industr

    1/30/26 8:45:00 AM ET
    $CRML
    Metal Mining
    Basic Materials

    Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

    Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham

    1/8/26 4:30:00 PM ET
    $ARVN
    $DGX
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Biotechnology: Laboratory Analytical Instruments

    $ARQT
    $ARVN
    $BCRX
    $BGS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Candel Therapeutics Inc.

    SC 13G - Candel Therapeutics, Inc. (0001841387) (Subject)

    12/17/24 12:30:40 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by Critical Metals Corp.

    SC 13D/A - Critical Metals Corp. (0001951089) (Subject)

    12/13/24 4:10:59 PM ET
    $CRML
    Metal Mining
    Basic Materials

    Amendment: SEC Form SC 13G/A filed by Cabaletta Bio Inc.

    SC 13G/A - Cabaletta Bio, Inc. (0001759138) (Subject)

    12/6/24 4:05:57 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ARQT
    $ARVN
    $BCRX
    $BGS
    Financials

    Live finance-specific insights

    View All

    Nu Holdings Ltd. Reports Fourth Quarter and Full Year 2025 Financial Results

    Nu Holdings Ltd. (NYSE:NU) ("Nu" or the "Company"), one of the largest digital financial services platforms in the world, today released its financial results for the fourth quarter and full year ended December 31, 2025, prepared in accordance with IFRS, as well as complementary managerial1 results. The financial statements and earnings presentation are available on the Company's Investor Relations website at www.investors.nu, along with details of the earnings conference call to be held today at 5:00 p.m. Eastern Time / 7:00 p.m. Brasília time. "In Q4'25, we increased scale, deepened engagement, and expanded profitability, closing the year with 131 million customers and 17 million net ad

    2/25/26 4:50:00 PM ET
    $NU
    Finance: Consumer Services
    Finance

    Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    Q4 2025 net product revenue for ZORYVE® (roflumilast) was $127.5 million, an 84% increase compared to Q4 2024, and a 29% increase compared to Q3 2025Full year 2025 net product revenue for ZORYVE was $372.1 million, an increase of 123% over the prior yearReported positive topline data for the INTEGUMENT-INFANT Phase 2 trial of ZORYVE cream 0.05% in children ages 3 to 24 months with mild to moderate atopic dermatitis, with a Supplemental New Drug Application (sNDA) submission expected in Q2 2026Announced expansion of its dermatology sales force and, separately, the initiation of a targeted Arcutis commercialization effort for primary care and pediatric health care providersProduced positive op

    2/25/26 4:00:00 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    B&G Foods Announces Date of Fourth Quarter and Fiscal Year 2025 Earnings Conference Call

    B&G Foods, Inc. (NYSE:BGS) announced today that it intends to issue a press release with fourth quarter and fiscal year 2025 financial results after the market close on Tuesday, March 3, 2026. B&G Foods has scheduled a conference call at 4:30 p.m. ET that same day to discuss the results. Hosting the call will be Casey Keller, President and Chief Executive Officer and Bruce Wacha, Executive Vice President of Finance and Chief Financial Officer. The earnings press release and live audio webcast of the conference call can be accessed at www.bgfoods.com/investor-relations. A replay of the webcast will be available following the conference call through the same link. About B&G Foods, Inc. Ba

    2/24/26 5:30:00 PM ET
    $BGS
    Packaged Foods
    Consumer Staples